Answers are grounded in this paper and cite their sources.
Background Pleural effusion is a frequent complication of advanced lung cancer and is associated with poor prognosis. Although pleural effusion reflects a tumor-associated microenvironment and represents an attractive source for biomarker discovery, clinically useful prognostic biomarkers derived from pleural effusion remain limited. Transforming growth factor-β (TGF-β) plays a crucial role in tumor progression and immune regulation; however, the prognostic significance of individual TGF-β isoforms in pleural effusion has not been fully elucidated. Methods We retrospectively analyzed pleural effusion samples from 60 patients with lung cancer. Concentrations of TGF-β 1 , TGF-β 2 , and TGF-β 3 in pleural effusion were measured using a multiplex assay. Overall survival was evaluated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used to assess the prognostic significance of TGF-β isoforms after adjustment for clinical covariates. Results Pleural effusion concentrations of all three TGF-β isoforms showed substantial inter-individual variability and skewed distributions. Kaplan–Meier analyses demonstrated no significant differences in overall survival between high and low groups for any TGF-β isoform. However, in multivariable Cox models, higher pleural effusion TGF-β 2 levels were associated with poorer overall survival after adjustment for clinical covariates, whereas TGF-β 1 and TGF-β 3 were not independently associated with prognosis. Conclusion Among the three TGF-β isoforms examined, pleural effusion TGF-β 2 may serve as a candidate prognostic biomarker in patients with lung cancer accompanied by pleural effusion. Isoform-specific analysis of pleural effusion cytokines may provide clinically relevant prognostic information and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Okita et al. (2026) studied this question.